3-hour On-Demand: Fibromyalgia & Chronic Fatigue Syndrome
3-hour On-Demand: Fibromyalgia & Chronic Fatigue Syndrome is organized by CE International.
Expiration Date: 10-27-2024
Course Description & Information:
Fibromyalgia is one of the most common chronic pain conditions. The disorder affects an estimated 10 million people in the U.S. and an estimated 3-6% of the world population. While it is most prevalent in women —75-90 percent of the people who have FM are women —it also occurs in men and children of all ethnic groups. Fibromyalgia Syndrome is a chronic condition causing pain, stiffness, and tenderness of the muscles, tendons, and jointsChronic fatigue syndrome/myalgic encephalomyelitis is a complex, multi-system, chronic medical condition whose pathophysiology remains unknown. No established diagnostic tests exist nor are any FDA-approved drugs available for treatment. This course provides an evidence-based medicine approach to current research into understanding these two disorders and current treatment options that apply a patient-centered approach to care.
• Level: Intermediate
Course Objectives:
• Summarize recent updated guidelines for the diagnosis and treatment of fibromyalgia.
• Summarize recent updated guidelines for the diagnosis and treatment of chronic fatigue syndrome.
• List the medication treatment options for fibromyalgia, including indications and major adverse effects.
• Explain the underlying pathophysiology (central sensitization) of fibromyalgia.
• State non-medication treatment options for fibromyalgia and chronic fatigue syndrome.
• Explain the overall symptom complex and comorbidities associated with fibromyalgia.
• Identify symptoms common across all myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) case definitions.
• List the factors that make chronic fatigue syndrome difficult to diagnose.
• State the role of diet and nutritional supplements in the treatment of fibromyalgia and chronic fatigue syndrome.
• Summarize the data on the leaky gut, autoimmune disease and fibromyalgia.
Additional details will be posted as soon as information is available.